Screen LibraryBladder cancer : diagnosis and clinical management /
Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy...
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | ; ; |
| Published: |
Wiley Blackwell,
|
| Publisher Address: | Chichester, West Sussex : |
| Publication Dates: | 2015. |
| Literature type: | eBook |
| Language: | English |
| Subjects: | |
| Online Access: |
http://onlinelibrary.wiley.com/book/10.1002/9781118674826 |
| Summary: |
Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult. In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education. |
| Carrier Form: | 1 online resource |
| Bibliography: | Includes bibliographical references and index. |
| ISBN: |
9781118674864 1118674863 9781118674826 1118674820 9781118674857 1118674855 |
| Access: | Owing to Legal Deposit regulations this resource may only be accessed from within National Library of Scotland. For more information contact enquiries@nls.uk. |
| Index Number: | RC280 |
| CLC: | R737.14 |
| Contents: |
Diagnosis and treatment of non-muscle-invasive bladder cancer. Pathology / Risk stratification of high-grade Ta, CIS, and TI urothelial carcinoma of the bladder / Utility of urine biomarkers / Novel endoscopic techniques for the detection of bladder cancer / Transurethral resection of bladder tumors / Intravesical chemotherapy / Intravesical immunotherapy / HGT1 bladder cancer: Diagnosis and treatment / What to do when bacillus Calmette-Guerin fails / T2-4. Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction / Radical cystectomy: Techniques and outcomes / Cystectomy in the female patient / Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes / Robotic assisted radical cystectomy and urinary diversion: Clinical trials / Role of extended lymphadenectomy / Management of the urethra in the cystectomy patient / The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder / Primary bladder-sparing therapy. Radical transurethral resection / Partial cystectomy / Integrating chemotherapy and radiotherapy for bladder cancer / Urinary tract reconstruction. Orthotopic neobladder / Continent cutaneous diversion / Non-continent urinary diversion / Treatment of regionally advanced and metastatic bladder cancer. Molecular determinants of chemotherapy response / Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer / Adjuvant chemotherapy for invasive bladder cancer / Treatment of metastatic bladder cancer / Treatment of poor risk patients / Genomics and the current status of urothelial cancer. Molecular events in muscle-invasive bladder cancer development / Cancer stem cells and intrinsic subtypes in bladder cancer / Multi-targeted agents in the treatment of urothelial carcinoma / Optimizing healthcare delivery. Patient navigation and cancer navigator programs / Impact of health services on compliance and outcomes / Quality of life and survivorship / Bladder cancer: Healthcare delivery and third party payers / Bladder cancer patient advocacy: Creating partnerships to advance patient care, research, and clinical trials / |